Balaji Chinnasami1, Kanimozhi Sadasivam2, Aravindhan Vivekanandhan3, Prema Arunachalam4, Sekar Pasupathy5. 1. Associate Professor, Department of Paediatrics, SRM MCH& RC , Chennai, India . 2. Assistant Professor, Department of Physiology, SRM MCH& RC , Chennai, India . 3. Researcher, Department of Immunology and Molecular Biology, AU-KBC Research Centre, MIT Campus of Anna University , Chrompet, Chennai, India . 4. Former, Professor & HOD, Department of Paediatrics, SRM MCH& RC , Chennai, India . 5. Professor & HOD, Department of Paediatrics, SRM MCH& RC , Chennai, India .
Abstract
BACKGROUND AND OBJECTIVES: Owing to the limitations of the conventional polysaccharide vaccines, global efforts have been made to develop conjugated polysaccharide vaccines for typhoid. Duration of immune response induced by these vaccines is critical to define the efficacy and frequency of required booster dose. This study was done to determine the duration of immune response following vaccination with Salmonella Typhi Vi conjugate vaccine (Pedatyph™) in children and to assess the booster effect of second dose of conjugate typhoid vaccine. MATERIALS AND METHODS: Forty children were recalled from a cohort of 400 children, who received one dose or two doses of PedaTyph™, 30 months after vaccination. Ten non-vaccinated children were also recalled. Their serum samples were assessed by ELISA for anti Vi antibody. RESULTS: Significantly high titers of anti-Vi polysaccharide IgG antibodies were present in vaccinated children even after 30 months of vaccination as compared to non-vaccinated children. Geometric mean titers (GMT) with 95% confidence intervals were 14 (4.8-29.8), 17 (7.4-33) and 6.4 (0.8-12) μg/ml for single dose, two doses and control group respectively. The children in two doses group had higher antibody titers as compared to single dose group. However, the difference was not significant. INTERPRETATION AND CONCLUSION: PedaTyph™ was found to induce long term immune response as evidenced by presence of significant anti-Vi polysaccharide antibodies after 30 months of vaccination. No significant advantage of two doses regimen over one dose was found. Hence one dose vaccination with PedaTyph™ is suggested.
BACKGROUND AND OBJECTIVES: Owing to the limitations of the conventional polysaccharide vaccines, global efforts have been made to develop conjugated polysaccharide vaccines for typhoid. Duration of immune response induced by these vaccines is critical to define the efficacy and frequency of required booster dose. This study was done to determine the duration of immune response following vaccination with Salmonella Typhi Vi conjugate vaccine (Pedatyph™) in children and to assess the booster effect of second dose of conjugate typhoid vaccine. MATERIALS AND METHODS: Forty children were recalled from a cohort of 400 children, who received one dose or two doses of PedaTyph™, 30 months after vaccination. Ten non-vaccinated children were also recalled. Their serum samples were assessed by ELISA for anti Vi antibody. RESULTS: Significantly high titers of anti-Vi polysaccharide IgG antibodies were present in vaccinated children even after 30 months of vaccination as compared to non-vaccinated children. Geometric mean titers (GMT) with 95% confidence intervals were 14 (4.8-29.8), 17 (7.4-33) and 6.4 (0.8-12) μg/ml for single dose, two doses and control group respectively. The children in two doses group had higher antibody titers as compared to single dose group. However, the difference was not significant. INTERPRETATION AND CONCLUSION: PedaTyph™ was found to induce long term immune response as evidenced by presence of significant anti-Vi polysaccharide antibodies after 30 months of vaccination. No significant advantage of two doses regimen over one dose was found. Hence one dose vaccination with PedaTyph™ is suggested.
Authors: Vipin M Vashishtha; Panna Choudhury; Ajay Kalra; Anuradha Bose; Naveen Thacker; Vijay N Yewale; C P Bansal; Pravin J Mehta Journal: Indian Pediatr Date: 2014-10 Impact factor: 1.411
Authors: Ngoc Lanh Mai; Van Bay Phan; Anh Ho Vo; Cong Thanh Tran; Feng Ying C Lin; Dolores A Bryla; Chiayung Chu; Joseph Schiloach; John B Robbins; Rachel Schneerson; Shousun C Szu Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: A Sinha; S Sazawal; R Kumar; S Sood; V P Reddaiah; B Singh; M Rao; A Naficy; J D Clemens; M K Bhan Journal: Lancet Date: 1999-08-28 Impact factor: 79.321
Authors: S C Szu; D N Taylor; A C Trofa; J D Clements; J Shiloach; J C Sadoff; D A Bryla; J B Robbins Journal: Infect Immun Date: 1994-10 Impact factor: 3.441
Authors: Z Kossaczka; F Y Lin; V A Ho; N T Thuy; P Van Bay; T C Thanh; H B Khiem; D D Trach; A Karpas; S Hunt; D A Bryla; R Schneerson; J B Robbins; S C Szu Journal: Infect Immun Date: 1999-11 Impact factor: 3.609
Authors: So Jung An; Puthupparampil V Scaria; Beth Chen; Emma Barnafo; Olga Muratova; Charles Anderson; Lynn Lambert; Myung Hwa Chae; Jae Seung Yang; Patrick E Duffy Journal: Vaccine Date: 2018-04-20 Impact factor: 3.641
Authors: James E Meiring; Alberto Giubilini; Julian Savulescu; Virginia E Pitzer; Andrew J Pollard Journal: Clin Infect Dis Date: 2019-10-15 Impact factor: 9.079